Home Mapping point-of-care performance using locally-smoothed median and maximum absolute difference curves
Article
Licensed
Unlicensed Requires Authentication

Mapping point-of-care performance using locally-smoothed median and maximum absolute difference curves

  • Gerald J. Kost EMAIL logo , Nam K. Tran and Harpreet Singh
Published/Copyright: October 1, 2011

Abstract

Background: The goal is to introduce visual performance mapping efficient for establishing acceptance criteria and facilitating decisions regarding the utility of hospital point-of-care devices. This approach uniquely reveals the quality of performance locally, as opposed to globally.

Methods: After presenting theoretical foundations, this study illustrates the approach by applying it to six hospital glucose meter systems (GMSs) using clinical multi-center (n=2767) and multi-system (n=613, n=100) observations.

Results: LS MAD curves identified breakouts, that is, points where the locally-smoothed median absolute difference (LS MAD) curve exceeds the recommended error tolerance limit of 5 mg/dL (0.28 mmol/L). LS maximum absolute difference (MaxAD) breakthroughs, which occur where the LS MaxAD curve exceeds the 99th percentile of MaxADs from x=30–200 mg/dL (1.67–11.10 mmol/L), showed extreme error locations. A multi-sensor interference- and hematocrirt-correcting GMS displayed a flat LS MAD curve until it reached a breakout of 179 mg/dL (9.94 mmol/L) and generated breakthroughs that could affect bedside decision-making, but less erratically than other systems with inadequate performance for hospital critical care. We discovered Class I (meter high, reference low) and Class II (converse) discrepant values in some systems. Class I errors could lead to inappropriate insulin dosing and hypoglycemic episodes in tight glucose control.

Conclusions: LS MAD-MaxAD curves help assess the performance of point-of-care testing. Visual mapping of systematic and random errors locally over the entire analyte measurement range in a single integrated display is an advantage when considering the adverse impact of zones of poor quantitative performance on specific clinical applications, threshold-driven bedside decisions and the care of critically ill patients.


Corresponding author: Gerald J. Kost, MD, PhD, MS, FACB, POCT·CTR, Pathology and Laboratory Medicine, 3455 Tupper Hall, School of Medicine, University of California, Davis, CA 95616, USA Phone: +1-530-574-3945, Fax: +1-530-752-4548

Received: 2011-3-14
Accepted: 2011-5-20
Published Online: 2011-10-01
Published in Print: 2011-10-01

©2011 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Editorial
  2. Laboratory medicine: an essential partner in the care of cancer patients
  3. Reviews
  4. Circulating tumor cells as emerging tumor biomarkers in breast cancer
  5. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer
  6. Increased plasma concentrations of tumour markers in the absence of neoplasia
  7. Recent progress and clinical importance on pharmacogenetics in cancer therapy
  8. Genetics and Molecular Diagnostics
  9. Genotyping of the hemochromatosis HFE p.H63D and p.C282Y mutations by high-resolution melting with the Rotor-Gene 6000® instrument
  10. General Clinical Chemistry and Laboratory Medicine
  11. Mapping point-of-care performance using locally-smoothed median and maximum absolute difference curves
  12. The use of inflammatory markers as a method for discharging patients post hip or knee arthroplasty
  13. Significant elevation of plasma pentraxin 3 in patients with pelvic inflammatory disease
  14. Combined effects of coffee consumption and serum γ-glutamyltransferase on serum C-reactive protein in middle-aged and elderly Japanese men and women
  15. Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study
  16. Comparative evaluation of capillary zone electrophoresis and HPLC in the determination of carbohydrate-deficient transferrin
  17. Determinants of blood levels of some thrombogenic biomarkers in healthy Arab adolescent subjects
  18. Analytical performance of a multiplexed, bead-based cytokine detection system in small volume samples
  19. Diagnostic utility of a soluble cytokeratin 18 assay for gastrointestinal graft-vs.-host disease detection
  20. Cancer Diagnostics
  21. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer
  22. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells
  23. Serum APRIL, a potential tumor marker in pancreatic cancer
  24. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
  25. Infectious Diseases
  26. New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry
  27. Cardiovascular Diseases
  28. Association of a functional polymorphism in the MMP7 gene promoter with susceptibility to vulnerable carotid plaque in a Han Chinese Population
  29. Diabetes
  30. Glycated albumin may be a possible alternative to hemoglobin A1c in diabetic patients with anemia
  31. A simple micro-photometric method for urinary iodine determination
  32. Letters to the Editor
  33. Clinically needed sensitivity for very low levels of Factor XIII: not yet proven for a new functional assay
  34. Apolipoprotein A5-12238 T>C gene polymorphism and risk factors for metabolic syndrome in the Guo Shan Yao and the Han populations
  35. Congress Abstracts
  36. 10.1515/CCLM.2011.738
  37. 1st National Congress of Laboratory Medicine
Downloaded on 7.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.655/pdf
Scroll to top button